Skip to main content
. 2015 Dec 15;7(4):4806–4816. doi: 10.18632/oncotarget.6624

Figure 5. AntiangiomiRs.

Figure 5

A. Expression of miR-20b according to age at DLBCL diagnosis showed higher expression in patients aged >= 60 years (Mann-Whitney, p=0.0431); B. miR-328 expression according to molecular subtypes of Hans algorithm showing higher expression in ABC subtype (Mann-Whitney, p=0.0099); C. miR-16 expression in DLBCL according to CD34 (MVD - Manual counting) (p=0.0331, Mann-Whitney). The expression of CD34 (MVD) is ranked quartiles: I and II considered as low expression; III and IV considered as high expression. Number of cases examined = 80/84 (4 cases not available for CD34 expression); D. miR-16 expression in DLBCL according to stromal signature (p=0.0146, Mann-Whitney); E. miR-221 expression in DLBCL according to CD34 (MVD - manual counting) (p=0.0182, Mann-Whitney). The expression of CD34 (MVD) is ranked quartiles: I and II considered as low expression; III and IV considered as high expression. Number of cases analyzed = 80/84 (4 cases not available to CD34 expression); F. miR-221 expression in DLBCL according to stromal signature (p=0.0076, Mann-Whitney). G. Expression of miR-328 in DLBCL according to CD34 (MVD - manual counting) (p=0.0129, Mann Whitney). The expression of CD34 (MVD) is ranked quartiles: I and II considered as low expression; III and IV considered as high expression. Number of cases examined = 80/84 (4 cases not amenable for CD34 expression); H. miR-328 expression in DLBCL according to stromal signature (p=0.0099, Mann-Whitney).